MarketLens

Spyre Therapeutics: Why Insiders Are Cashing Out Amidst a $5 Billion Valuation

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Executive Exodus: Why GLOBALFOUNDRIES Insiders Are Cashing Out

1 months ago

TransDigm: Why Insiders Are Cashing Out After Exercising Options

1 months ago

What Do Recent Insider Sales at Spyre Therapeutics Signal

4 months ago

Insight's Strategic Exit: Why a Major Investor is Cashing Out of Hinge Health

1 months ago

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Spyre Therapeutics reported Q2 2026 results and announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial, showing best-in-class efficacy potential and a...

SYRE

Stock News•1 months ago

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio priced a $200M public offering of ~11M shares and pre-funded warrants at $18.25/share, diluting existing holders to fund clinical development.

QTTB

Stock News•1 months ago

Kymera's CEO Sold $6 Million in Stock After a 170% Run

Kymera CEO sold ~$6M in stock after a 170% run, exercising 50,000 shares at $119 on July 7. The sale reduced direct holdings by 7%.

KYMR

News•1 months ago

Corporate America is pumping $1 trillion into stock buybacks — but look at what insiders are doing

Corporate America is spending $1 trillion on stock buybacks, but insider selling at 22 U.S. stocks signals a potential disconnect between corporate and executive confidence.